Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Inclusion Criteria: * Primary liver cancer diagnosed according to the clinical diagnostic criteria, or histopathological or cytological examination; * 18-80 years old, no limit on gender; * ECOG performance status of 0-2, with expected survival time of more than 12 weeks; * According to RECIST V1.1, there must be at least one measurable lesion; * Patients who are suitable for ICIs treatment and willing to comply with required protocols and give permission to use the data for clinical research and products development; * Patients who join the study voluntarily, sign a consent form, have good compliance, and comply with follow-up. Exclusion Criteria: * Patients with other primary cancers; * Patients with a severe parenchymal disease and unable to accept ICIs treatment; * Patients with a psychiatric disorder and unable to comply with this study; * Patients with symptomatic brain metastasis, anticipated complications or cognitive disorders that are associated with brain metastasis; * Adverse events related to prior anti-tumor treatment (except for hair loss of any grade) did not return to grade 1 or better; * History of cells or organ transplantation; * History of hypersensitivity to the drug administered in this study or contrast media for CT and MRI; * Patients who accepted hepatic local therapy (including ablation therapy, percutaneous injection of ethanol or acetic acid (PEI/PAI), high-intensity focused ultrasound (HIFU), transarterial chemoembolization (TACE)) within 14 days prior to initiation of the study; * Other reasons that the researchers think not suitable for ICIs treatment